With false positive rates of 18% and 3% based on the mean+SD and mean+2 SD of control subjects, the net detection rate was 49% and 35% for DCIS, 49% and 37% for HER2+, 55% and 57% for TNBC and 55% and 40% for ER+/PR+/HER2- cancers. Here, ERBB2 is linked to ductal breast carcinoma in situ.